Bristol-myers Squibb Compnay

E. R. Squibb Sons, Inc.

Medarex Inc.

Ono Pharmaceutical Co., Ltd.

Five Prime Therapeutics, Inc.

N.v. Organon

Biosante Pharmaceuticals, Inc.

Aduro Gvax Inc.

Providence Health & Services

Alan J Korman

Mark J Selby

Mohan Srinivasan

Haichun Huang

Guodong Chen

Richard Y Huang

Changyu Wang

Nils Lonberg

Karla Ann Henning

Michelle Minhua Han

Kent B Thudium

Huiming Li

Josephine M Cardarelli

Heidi N Leblanc

Indrani Chakraborty

Edward L Halk

Ekaterina G Deyanova

Christine Bee

Paul O Sheppard

Mark Yamanaka

Kyra D Zens

David B Passmore

Michelle Renee Kuhne

Tibor P Keler

Ginger Chao Rakestraw

Bingliang Chen

Xiao Min Schebye

Andy X Deng

Arvind Rajpal

Aaron Paul Yamniuk

Haibin Chen

Bryan C Barnhart

Susan Wong

Ming Lei

Andrew Rankin

John J Engelhardt

Sandra V Hatcher

Hong-An Truong

Xiang Shao

Susan Chien-Szu Wong

Liang Schweizer

Brigitte Devaux

Yashwant M Deo

Xi-Tao Wang

Brenda L Stevens

Keith Sadoon Bahjat

Daniel F Ardourel

Anan Chuntharapai

Mary Diane Feingersh

Maria N Jure-Kunkel

Martin J Corbett

Shrikant Deshpande

Li-Sheng Lu

John S Sack

Michael Quigley

Robert J Johnston

Lin Hui Su

Luis Borges

Xiaodi Deng

Natalie Bezman

Joseph E Myers, Jr

Pingping Zhang

Hadia Lemar

Emanuela Sega

Angela Goodenough

Peter Brams

Han Chang

Alison Witte

Robert F Graziano

Mark F Maurer

Andrea Van Elsas

Jennifer Marie Mataraza

Jochem Gokemeijer

Alexander T Kozhich

Dawn M Tanamachi

Thomas D Kempe

Vangipuram S Rangan

Timothy W Sproul

Zhehong Cai

Marie-Michelle Navarro Garcia

Christina Maria Milburn

Patrick Guirnalda

Amy D Jhatakia

Karin Ute Jooss

Linda Liang

Katherine E Lewis

David J Fontana

Joseph Toth

Bing Chen

Jason Robert Pinckney

Betty Li

Diana Yuhui Chen

Olufemi A Adelakun

Pavel Strop

Sarah Lee Pogue

Kristopher Toy

Akbar Nayeem

Lan Yang

Richard Yu-Cheng Huang

Jun Zhang

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to ILT4

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to VISTA at acidic pH

Antibodies binding to vista at acidic pH

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.

Anti-ICOS agonist antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Growing community of inventors

Piedmont, CA, United States of America

Alan J Korman